| Bioactivity | di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients[1][2][3]. |
| Name | di-DTPA-LTL |
| Formula | C52H82N12O23 |
| Molar Mass | 1243.27 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gruaz-Guyon A, et al. Recent advances in pretargeted radioimmunotherapy. Curr Med Chem. 2005;12(3):319-38. [2]. Gautherot E, et al. Therapy for colon carcinoma xenografts with bispecific antibody‐targeted, iodine‐131‐labeled bivalent hapten[J]. Cancer: Interdisciplinary International Journal of the American Cancer Society, 1997, 80(S12): 2618-2623. [3]. Aarts F, et al. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti‐di‐diethylenetriaminepentaacetic acid F (ab′) 2 antibody[J]. Cancer, 2010, 116(S4): 1111-1117. |